Annual Report 2012 Active Biotech AB (publ)

LUND, SWEDEN–(Marketwired – Apr 15, 2013) – Active Biotech’s
Annual Report 2012 (in Swedish) is now available for download at
The English version will be available within short.

The Annual Report will only be digitally distributed.

Lund, April 15, 2013

Active Biotech AB (publ)

Tomas Leanderson President & CEO

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology
company with focus on autoimmune/inflammatory diseases and cancer.
Projects in pivotal phase are laquinimod, an orally administered
small molecule with unique immunomodulatory properties for the
treatment of multiple sclerosis, tasquinimod for prostate cancer
and ANYARA primarily for the treatment of renal cell cancer. In
addition, laquinimod is in Phase II development for Crohn’s and
Lupus. The company also has one additional project in clinical
development, the orally administered compound 57-57 for Systemic
Sclerosis. Please visit
more information.

Active Biotech AB (Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund

Tel: +46 46 19 20 00

Fax: +46 46 19 11 00

Active Biotech is required under the Financial Instruments
Trading Act to make the information in this press release public.
The information was submitted for publication at 10:00 a.m. CET on
April 15, 2013.

Annual Report 2012 Active Biotech AB (publ):

This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants

(i) the releases contained herein are protected by copyright and
other applicable laws; and

(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE


For further information, please contact:

Hans Kolam


Tel +46 (0)46 19 20 44

If you enjoyed this post, please consider leaving a comment or subscribing to the RSS feed to have future articles delivered to your feed reader.